Friedrich Markus, Sterry Wolfram, Asadullah Khusru
Psoriasis Studienzentrum, Klinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Charité, Schumannstr. 20/21, 10117 Berlin, Germany.
J Dtsch Dermatol Ges. 2003 Jan;1(1):12-21. doi: 10.1046/j.1610-0387.2003.t01-1-02024.x.
The current standard systemic therapeutic modalities for psoriasis have many potential side effects. Progress made in the understanding of the pathophysiology of psoriasis as a T-cell-mediated dermatosis provide options for new more precise therapeutic approaches. These immunological therapeutic strategies involve the inhibition/depletion of activated T-lymphocytes, the inhibition of antigen presentation and thus the regulation of T-cell activation, the inhibition of adhesion of inflammatory cells, the inhibition of effects of proinflammatory mediators and the administration of antiinflammatory cytokines. This article summarizes these new systemic therapeutic approaches. Clinical results in the early studies have been mixed. In the next years further results of phase II- and phase Ill-studies may be expected, which should allow better assessment of the potential of those particular approaches. Some of these approaches could lead to the approval of new drugs to treat psoriasis and to enhance or replace already existing therapeutic options. Furthermore results of therapeutic experiments should contribute to a better understanding of the disease. As we learn which mechanisms are more or less important for the disease, we will be better able to plan intervention strategies.
目前用于治疗银屑病的标准全身治疗方法有许多潜在的副作用。对银屑病作为一种T细胞介导的皮肤病的病理生理学认识的进展为新的更精确的治疗方法提供了选择。这些免疫治疗策略包括抑制/清除活化的T淋巴细胞、抑制抗原呈递从而调节T细胞活化、抑制炎性细胞的黏附、抑制促炎介质的作用以及给予抗炎细胞因子。本文总结了这些新的全身治疗方法。早期研究的临床结果喜忧参半。在未来几年，可能会有II期和III期研究的进一步结果，这将有助于更好地评估这些特定方法的潜力。其中一些方法可能会导致治疗银屑病的新药获批，并增强或取代现有的治疗选择。此外，治疗实验的结果应有助于更好地理解该疾病。随着我们了解哪些机制对该疾病或多或少重要，我们将能够更好地规划干预策略。
